bullish

Starpharma Holdings (SPL AU): Ready to Fly High as Viraleze Anti-Viral Nasal Spray Relaunched in UK

445 Views01 Jul 2022 15:41
SUMMARY
  • Starpharma Holdings (SPL AU) is an emerging biopharma company. The company has commercialized its flagship product Viraleze antiviral nasal spray in March 2021. It is now registered in 30+ countries.
  • On June 30, Starpharma announced the relaunch of Viraleze in UK, one-year after its sales were paused temporarily in June 2021, thereby removing a major overhang on the share prices.
  • Viraleze has shown strong potential to inactivate a broad spectrum of respiratory/cold viruses, including multiple variants of SARS-CoV-2 and influenza A and B.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
chart-bar
Logo
Rising
Tina Banerjee
Global Healthcare Analyst
Health CareEquity Bottom-UpThematic (Sector/Industry)
  • Starpharma Holdings (SPL AU): Ready to Fly High as Viraleze Anti-Viral Nasal Spray Relaunched in UK
    01 Jul 2022
x